PROM1 and colorectal carcinoma: Additionally known is that the CD133+ CRC cell population resists anti-angiogenesis therapy, and this resistance occurs through an anti-apoptotic pathway including PP2A, p38MAPK, MAPKAPK2, and Hsp27 [308].